No conflict of interest to disclose - Concepts in Vascular...

27

Transcript of No conflict of interest to disclose - Concepts in Vascular...

Page 1: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.
Page 2: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

No conflict of interest to disclose

Page 3: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

A question for you…

• A show of hands please…• How many people want incisions all over your

leg to cut out varicose veins (in the office, under straight local anesthesia – no IV sedation) when something non surgical will suffice?

• That concludes my talk –thank you very much

Page 4: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

It looks like I have some time left over

• Let me get this straight• Started dong vein ablations to avoid vein

stripping surgery• Heavily promoted vein ablation as a non

surgical therapy• Does he now recommend surgical therapy for

varicose veins immediately upon doing a non surgical therapy for varicose veins?

Page 5: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

Seems like…

Page 6: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

I know he likes cars, but…

Page 7: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

Our aim is the same: maximum symptomatic relief for as long as

possible• What is the ideal treatment?– Minimally invasive– Safe– Effective• functional• cosmetic

– Low recurrence rate– Cost effective

Page 8: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

Debate: residual superficial varicosities may remain. Then what?

Simultaneous treatment• Ensures treatment in a

single session.• Reduces the varicosity

reservoir.• Increased procedure time.• Over-treats patients whose

varicosities may regress.

Observation and delayed treatment if needed

• Shorter ablation time• A variable number of

patients return with residual varicosities that require secondary procedures.

Page 9: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

Scant evidence

• Randomized trial: No difference in QOL measures.– Carradice, BJS 2009;96:369-75

• 41% of patients did not require further treatment (a needless phlebectomy.)– Monahan, JVS 2005;42:1145-9

• Further studies needed, evidence unclear.– Editorial “Phlebectomies: to delay or not to

delay?” Davies, Phlebology 2012;27:103-4

Page 10: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.
Page 11: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.
Page 12: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.
Page 13: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.
Page 14: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.
Page 15: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.
Page 16: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

Phlebectomy

• Surgical removal of a vein – cut and sew

Page 17: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.
Page 18: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.
Page 19: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.
Page 20: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

FNP

Page 21: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

My current preference is neither

• I don’t prefer phlebectomy and I don’t prefer to wait and see.

• I do advocate for maximizing effective treatment strategy at the first opportunity.

• I prefer to combine endovenousvein ablation with foam sclerotherapy (specifically: Varithena)

Page 22: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.
Page 23: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

2 Months post EVLT + Varithena

Page 24: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

6 weeks post EVLT + Varithena

Page 25: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

6 weeks post EVLT + Varithena

Page 26: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

Summary and conclusions

• Concomitant phlebectomy with vein ablation may be unnecessary as a significant proportion of varices resolve with time.

• Variceal recurrence is not uncommon– Wait and see => subsequent sclerotherapy (or

phlebectomy) can be offered to those that need it.– vein ablation results are enhanced by immediate

adjunctive foam sclerotherapy.

Page 27: No conflict of interest to disclose - Concepts in Vascular ...conceptsinvasculartherapies.com/pdf/2019/Symposium...Scant evidence •Randomized trial: No difference in QOL measures.

Thank you